regulatory
confidence high
sentiment negative
materiality 0.60
Matinas BioPharma receives NYSE American non-compliance notice for equity below $2M
Matinas BioPharma Holdings, Inc.
- Received notice Aug 31, 2026: stockholders' equity $1.8M as of June 30, 2026, below $2.0M minimum under Section 1003(a)(i).
- Also non-compliant with Sections 1003(a)(ii) and (iii) (equity below $4M and $6M) as previously disclosed.
- Plan accepted by NYSE American; plan period through Oct 2, 2027 to regain compliance; delisting proceedings if not.
- No immediate impact on listing; shares continue trading on NYSE American under MTNB with .BC indicator.